Artemisinin-Based Combination Therapies in Uncomplicated Malaria
Summary
Artemisinin-based combination therapies (ACTs) are the cornerstone of treatment for uncomplicated Plasmodium falciparum malaria. Each regimen combines a fast-acting artemisinin derivative with a longer-acting partner drug, achieving rapid parasite clearance while suppressing the emergence of resistance. Common combinations include artemether–lumefantrine, artesunate–amodiaquine and dihydroartemisinin–piperaquine. Artemisinin components deliver rapid reduction of parasitaemia within the first 48 hours, alleviating clinical symptoms and interrupting transmission. Partner drugs extend post-treatment prophylaxis, reducing the risk of recrudescence and delaying new infections. Geographic variations in transmission intensity, drug pharmacodynamics and host immunity influence efficacy outcomes, prompting region-specific policy decisions. Regular therapeutic efficacy studies underpin national treatment guidelines, detect shifts in parasite susceptibility and guide the introduction of alternative combinations. The global success of ACTs has driven marked reductions in malaria mortality over the past two decades, yet the threat of emerging resistance and variable half-lives of partner compounds demand continuous surveillance and optimisation of treatment strategies.
Research from Nature Portfolio
A model-based analysis has compared cost-effectiveness and transmission impact of artemether–lumefantrine versus dihydroartemisinin–piperaquine across diverse African settings. By integrating pharmacokinetic-pharmacodynamic profiles, transmission-reducing effects and local epidemiological data, the study showed that dihydroartemisinin–piperaquine generally confers longer protection against reinfection, while artemether–lumefantrine more effectively curbs infectiousness. Simulations suggest that tailoring first-line regimens to local transmission intensity and seasonality can maximise cases averted at acceptable cost thresholds. This work underscores the importance of combining clinical trial evidence with dynamic models to inform context-specific antimalarial policies.
Artemisinin-Based Combination Therapies in Uncomplicated Malaria publication trend
The graph below shows the total number of articles in artemisinin-based combination therapies in uncomplicated malaria across all publications each year (not limited to Nature Index journals).
Technical terms
Artemisinin derivative: A fast-acting antimalarial compound extracted from the plant Artemisia annua, responsible for rapid reduction of parasite burden.
Partner drug: A longer-acting antimalarial combined with artemisinin to eliminate residual parasites and prevent recrudescence.
Recrudescence: Recurrence of malaria symptoms and parasitaemia due to incomplete clearance of the original infection.
Reinfection: A new malaria infection acquired after treatment, distinguished from recrudescence by molecular genotyping.
Pharmacokinetics-pharmacodynamics: The relationship between drug concentration over time and its biological effects on parasite clearance and transmission.
References
- Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nature Communications (2014).
- Therapeutic efficacy of dihydroartemisinin-piperaquine combination for the treatment of uncomplicated malaria in Ghana. Frontiers in Cellular and Infection Microbiology (2023).
- Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019. Malaria Journal (2024).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.